With trial win for oral thalassemia drug, Agios charts broader path than gene therapy rivals

cafead

Administrator
Staff member
  • cafead   Jan 03, 2024 at 05:12: PM
via Gene therapies have been approved for certain patients with beta thalassemia. After a successful phase 3 readout, Agios hopes it can reach a unique subgroup and eventually all patients.

Agios’ mitapivat significantly increased blood hemoglobin levels in more patients than placebo did in patients with either alpha- or beta-thalassemia that were not dependent on transfusion, Agios said Wednesday.

article source